AzTrials
AzTrials

Severe SepsisNCT01717651

Muscle Atrophy in Patients With Severe Sepsis

An observational study of Severe Sepsis and Respiratory Failure, run by Ohio State University at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study is being done to help determine whether patients with severe sepsis (overwhelming inflammation in the body as a result of an infection) lose muscle and become weak more rapidly than patients with other severe illnesses. Weakness and muscle loss that develops after a severe illness is a serious problem. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Severe Sepsis, Respiratory Failure
How many people
25 participants
Where
1 siteUnited States
Study dates
Dec 2011to Feb 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: A) Inclusion Criteria 1. Age ≥ 18 years 2. Required mechanical ventilation for at least 24 hours

  1. Inclusion Criteria
  2. Age ≥ 18 years
  3. Required mechanical ventilation for at least 24 hours
  4. Exclusion Criteria
  5. Ventilator liberation anticipated in the next 24 hours
  6. Rationale: short duration of illness anticipated, preventing achievement of primary endpoint
  7. Known or suspected acute diagnosis of neuromuscular disease causing diffuse or lower extremity weakness (e.g. CVA, spinal cord injury or lesion, Muscular dystrophy, Myasthenia Gravis, GBS)
  8. Rationale: chronic lower extremity weakness will impact anticipated physical recovery and relevance of atrophy observations
  9. Pre-existing lower extremity weakness caused by prior injury, neuromuscular or joint disease
  10. Rationale: Inability to participate in usual care therapy and CPM. Impacts functional recovery
  11. Wounds, dressings or injuries of the lower extremities or pelvis that prevent muscle testing or CPM
  12. Rationale: Inability to participate in US, exam or CPM
  13. Patient's family, physician, or both not in favor of aggressive treatment of patient that includes life-sustaining treatments or the presence of an advance directive indicating the same a. Rationale: Unlikely to survive to seven day endpoint
  14. More than seventy-two hours of continuous mechanical ventilation previously during this hospitalization
  15. Rationale: Atrophy mechanisms already active and may degrade ability to detect early changes.
  16. Non-English speaking subject or legally authorized representative
  17. Rationale: This study does not have the funding necessary to translate consents and inability to ensure cooperation with testing.
  18. Subject and/or Legally authorized representative unavailable to provide informed consent
  19. Subject is a Prisoner
  20. Pregnancy (excluded from CPM portion only) a. Rationale: Pregnant patients can develop the supine hypotensive syndrome (where the uterus compromises venous return due to compression of the IVC). This typically occurs only after 20 weeks gestation. To assure safety, any patient who self identifies as pregnant or has a positive urine pregnancy test on admission will not be offered CPM since it requires extended periods in the supine position.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The Ohio State University Medical Center - University Hospital

    Columbus, Ohio, 43210

Other trials in United States

About this study

This study is being done to help determine whether patients with severe sepsis (overwhelming inflammation in the body as a result of an infection) lose muscle and become weak more rapidly than patients with other severe illnesses. Weakness and muscle loss that develops after a severe illness is a serious problem. Patients who develop weakness and have a decrease in muscle size often have to stay in the hospital longer and have a higher chance of dying. At the current time, it is not clear whether certain severe illnesses are more likely to cause weakness and muscle loss. This study will be done to measure the changes in muscle size and strength as a result of each patient's illness

Read the detailed description

An optional portion of the study is available to help determine if moving the leg repeatedly with a mechanical device helps prevent muscle loss and weakness. In this optional portion of the study, the subject would have a CPM (continuous passive motion) device attached to one of the subject's legs intermittently over the next three days. Without any effort from the subject , the machine would move the subjects leg back and forth (flexing at the hip and the knee) repeatedly.

This machine is approved by the United States Food and Drug Administration (FDA) to treat patients after they have knee replacement surgery to help preserve the range of motion of the joint while minimizing risk of damage to the joint from more intensive exercise. The use of the device for this study is investigational.

Keywords
Atrophy, Muscle wasting, Sepsis
Medical subject headings
Sepsis, Respiratory Insufficiency, Atrophy, Muscular Atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01717651
Study groupRoleWhat they receive
CPM devicea CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quadriceps muscle cross sectional area change from day 0 to 7

    Serial measures of quadriceps muscle by non-invasive ultrasound on Day of enrollment and Day 7 after enrollment

    Measured: seven days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2012 (estimated)
  2. Study startDec 2011
  3. Primary completionFeb 2013
  4. Study completionFeb 2013

Why it stopped: slow accrual made study completion unfeasible

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01717651
Sponsor's protocol ID
2011H0290
Status last verified
Jan 2016
First submitted
4 Oct 2012
Last updated
18 Jan 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Severe Sepsis and Respiratory Failure, run by Ohio State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 18 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: slow accrual made study completion unfeasible). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quadriceps muscle cross sectional area change from day 0 to 7 (time frame: seven days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in